Oslo Cancer Cluster member Vaccibody is entering into a clinical collaboration with the American biopharmaceutical company Nektar Therapeutics.
The aim of the collaboration is to explore positive effects from the combination of Vaccibody ’s personalized cancer vaccine VB10.NEO  and Nektar Therapeutics  cancer drug NKTR-214. Pre-clinical results of the combination are very positive and the collaboration will mark the start of a clinical trial stage.
The clinical trials will include patients with head and neck cancer and initially involve 10 patients.
What is Nektar?
Nektar Therapeutics is not just any company when it comes to immunotherapy. At Nasdaq their market value is set as high as 10 billion dollars.
– For a year now, Nektar might be the most talked about company within immunotherapy and this winter they landed the largest deal of its kind with Bristol Meyers-Squibb (BMS), says Agnete Fredriksen, President and Chief Scientific Officer, in an interview with Norwegian newspaper Finansavisen.
Help more patients
BMS and Nektar started collaborating on the development of the immunotherapy drug NKTR-214, the same drug that is part of the collaboration with Vaccibody, with a potential worth of 3.6 billion dollars.
– That they want to work with us is a nice validation of Vaccibody and makes us able to help even more cancer patients. We hope the combination of our products will lead to even better treatments, Agnete Fredriksen says to Finansavisen.
Nektar and Vaccibody each will maintain ownership of their own compounds in the clinical collaboration, and the two companies will jointly own clinical data that relate to the combination of their respective technologies. Under the terms of the agreement and following the completion of the pilot study, the two companies will evaluate if they will take the partnership to the next stage.